Minerva Neurosciences Redesigns Phase III Trial for Roluperidone

Minerva Neurosciences is moving to revive its schizophrenia drug candidate, roluperidone, by launching a redesigned confirmatory Phase III program following a previous regulatory rejection. The company aims to address the negative symptoms of schizophrenia, a condition affecting approximately 3 million people in the U.S. that remains a clinical challenge.

Minerva's previous attempt at Phase III testing failed to satisfy the FDA's statistical requirements. It missed the prespecified P value threshold of 0.025 by achieving 0.043 after the Hochberg correction. The company is now seeking to demonstrate efficacy through a revamped study structure. This includes a 12-week efficacy trial, known as Phase III-A, and a 52-week relapse comparison study, known as Phase III-B.

"The effect sizes were above 0.5, which is quite unheard of in psychiatry," said Rémy Luthringer, CEO of Minerva Neurosciences, during the Cantor Global Healthcare Conference.

Targeting Negative Symptoms

Negative symptoms of schizophrenia, such as anhedonia and low motivation, represent a 70-year unmet medical need. While current antipsychotic medications focus on positive symptoms like hallucinations and delusions, few treatments have targeted the social withdrawal and emotional flattening associated with negative symptoms.

Clinical Trial Strategy

The new regulatory pathway provides the clinical evidence requested by the FDA in its previous complete response letter. By splitting the program into two distinct phases, Minerva intends to capture short-term symptomatic improvement and long-term maintenance of effect.

Investors and clinicians are looking toward the second half of 2025. The company expects to report top-line results for the Phase III-A efficacy study at that time. This data will be critical in determining whether the drug can overcome the statistical hurdles that stalled its previous application.